Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-12, Vol.383 (26), p.2557-2570
1. Verfasser:	Burstein, Harold J
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Antiestrogens Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer therapies Cell growth Chemotherapy Chemotherapy, Adjuvant - adverse effects Endocrine therapy ErbB-2 protein Estrogen Receptor Antagonists - adverse effects Estrogen Receptor Antagonists - therapeutic use Estrogen receptors Estrogens Female Gene expression Humans Mammography Mastectomy Medical prognosis Metastasis Mutation Neoadjuvant Therapy Ovaries Progesterone Prognosis Radiation therapy Receptor, ErbB-2 - metabolism Receptors, Estrogen - antagonists & inhibitors Receptors, Estrogen - metabolism Selective Estrogen Receptor Modulators - adverse effects Selective Estrogen Receptor Modulators - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMra1307118